Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of ritlecitinib in adults with nonsegmental vitiligo
CTR20233947Phase 3Active
- Sponsor
- Pfizer
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ritlecitinib tosilate in nonsegmental vitiligo, sponsored by Pfizer. Started Jan 2024; status: active.
02
Drugs
ritlecitinib tosilate
03
Conditions
nonsegmental vitiligo
Beyond the preview
Go deeper on CTR20233947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233947.